Aclacinomycin A hydrochloride

SKU: orb1992962

Description

Aclarubicin hydrochloride is an anthracycline antibiotic that inhibits topoisomerase I/II and the 20S proteasome, disrupting DNA processes and generating ROS. It is used in research for studying relapsed leukemia and advanced lymphoma, with applications in both in vitro and in vivo models of oncology and cancer pharmacology.

Research Area

Cell Biology, Immunology & Inflammation, Infectious Disease & Virology, Molecular Biology, Protein Biochemistry

Images & Validation

−

Key Properties

−

CAS Number	75443-99-1
MW	848.33
Formula	C₄₂H₅₄ClNO₁₅
SMILES	C(OC)(=O)[C@@H]1C2=C([C@@H](O[C@H]3C[C@H](N(C)C)[C@H](O[C@H]4C[C@H](O)[C@H](O[C@@H]5O[C@@H](C)C(=O)CC5)[C@H](C)O4)[C@H](C)O3)C[C@@]1(CC)O)C(O)=C6C(=C2)C(=O)C=7C(C6=O)=C(O)C=CC7.Cl
Target	Topoisomerase,ROS,Proteasome,DNA,Antibiotic,DNA/RNA Synthesis
Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (4.72 mM);DMSO:120 mg/mL (141.45 mM)

Bioactivity

−

In Vivo	Method: P-388 leukemia cells were transplanted into DBA/2 and CDF1 (BALB/c × DBA/2) mice. Starting 3 hours after transplantation, mice received daily intraperitoneal injections of Aclacinomycin A hydrochloride for 10 consecutive days at doses of 0.75, 1.5, 3, and 6 mg/kg. Result: Aclacinomycin A hydrochloride significantly inhibited tumor growth in a dose-dependent manner. Read more...
In Vitro	Method: A cell viability assay was performed using V79 and irs-2 cell lines. Cells were treated with varying concentrations of Aclacinomycin A hydrochloride at 0, 0.006, 0.12, 1.2, and 2.4 μM for 3 hours. The effect on the catalytic activity of topoisomerase II (topo II) was evaluated. Result: Aclacinomycin A hydrochloride significantly inhibited topo II catalytic activity in a dose-dependent manner. Compared to the untreated group, all treated groups showed a statistically significant decrease in topo II activity, indicating that the drug effectively interferes with topo II function and subsequently affects cell viability. Read more...
Animal Research	Animal Model: DBA/2, CDF1 (BALB/c×DBA/2) mice with Leukemia P-388. Dosage: 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg. Administration: Intraperitoneal administration daily for 10 days starting 3 hr after transplantation. Result: Inhibited tumor growth . Read more...

Storage & Handling

−

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Aclarubicin hydrochloride

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

153751 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols